BRIEF published on 12/19/2025 at 12:05, 4 months 27 days ago Biotest AG Announces FDA Approval of Grifols' Fesilty™ FDA Approval Biotest AG U.S. Market Grifols Fibrinogen Therapy
PRESS RELEASE published on 12/19/2025 at 12:00, 4 months 27 days ago Biotest announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) Biotest AG announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) for acute bleeding episodes in patients with fibrinogen deficiency Biotest AG Fibrinogen Grifols US FDA Approval Fesilty
BRIEF published on 11/13/2025 at 10:12, 6 months 2 days ago Biotest Obtains Approval for Prufibry® in Germany Clinical Trials Biotest AG German Market Prufibry® Approval Fibrinogen Deficiency
PRESS RELEASE published on 11/13/2025 at 10:07, 6 months 2 days ago Biotest obtains approval for new human fibrinogen Prufibry® in Germany Biotest AG obtains approval in Germany for new human fibrinogen Prufibry®, expanding intensive care and coagulation factor portfolio with a life-saving therapy for congenital and acquired fibrinogen deficiency Germany Biotest AG Approval Human Fibrinogen Prufibry
BRIEF published on 11/07/2025 at 15:24, 6 months 7 days ago Biotest AG Schedules Extraordinary General Meeting at Grifols' Request Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
PRESS RELEASE published on 11/07/2025 at 15:19, 6 months 7 days ago Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A. Biotest AG convenes an extraordinary general meeting at the request of Grifols S.A. to discuss changing its legal form to a partnership limited by shares (KGaA) on 17 December 2025 Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
BRIEF published on 10/23/2025 at 13:21, 6 months 23 days ago Biotest AG Cancels Extraordinary General Meeting Grifols S.A. Extraordinary General Meeting Legal Form Change Corporate Restructuring Biotest AG News
PRESS RELEASE published on 10/23/2025 at 13:16, 6 months 23 days ago Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025 Biotest AG cancels extraordinary general meeting scheduled for 28 October 2025 following withdrawal of convocation request by Grifols S.A Grifols S.A. Cancellation Extraordinary General Meeting Biotest AG Legal Form Change
BRIEF published on 10/09/2025 at 17:35, 7 months 5 days ago Biotest's Yimmugo® Enters the U.S. Market Biotest AG U.S. Market Yimmugo® Launch Primary Immunodeficiencies Plasma-derived Medicines
PRESS RELEASE published on 10/09/2025 at 17:30, 7 months 5 days ago Biotest’s Yimmugo® launches in the United States Biotest AG launches Yimmugo®, a polyvalent human normal immunoglobulin (IVIg) for primary immunodeficiencies in the U.S., marking a significant milestone for the company's global growth strategy Biotest AG Yimmugo U.S. Launch Primary Immunodeficiencies IVIg
Published on 05/15/2026 at 14:35, 10 minutes ago NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
Published on 05/15/2026 at 14:30, 15 minutes ago AIAI Holdings Corporation Expresses Appreciation to Revere Securities for Financial Advisory Support on Successful NASDAQ Direct Listing
Published on 05/15/2026 at 14:00, 45 minutes ago CCL Industries Announces 2026 Annual and Special Shareholders' Meeting Results
Published on 05/15/2026 at 14:00, 45 minutes ago First Canadian Graphite to Attend the Mining Investment Event in Quebec City
Published on 05/15/2026 at 14:33, 12 minutes ago TAKKT expands Management Board: Helmar Hipp takes charge of Industrial & Packaging
Published on 05/15/2026 at 13:00, 1 hour 45 minutes ago Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
Published on 05/15/2026 at 12:47, 1 hour 57 minutes ago REPLY: The Board of Directors approves the quarterly report dated 31 March 2026
Published on 05/15/2026 at 12:07, 2 hours 38 minutes ago Original-Research: Almonty Industries Inc. (von Sphene Capital GmbH): Buy
Published on 05/15/2026 at 11:56, 2 hours 49 minutes ago Invitation to the Annual General Meeting on 16 June 2026
Published on 05/13/2026 at 17:45, 1 day 21 hours ago Infotel confirms its return to growth in Q1 2026 with revenue up 8.6%. Proposed dividend of €2 per share for 2025.
Published on 05/13/2026 at 17:45, 1 day 21 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2026
Published on 05/13/2026 at 17:40, 1 day 21 hours ago Report on share repurchases from 6 to 12 May 2026
Published on 05/13/2026 at 16:00, 1 day 22 hours ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
